![](/img/cover-not-exists.png)
489OOsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
Planchard, D, Boyer, M, Lee, J-S, Dechaphunkul, A, Cheema, P, Takahashi, T, Todd, A, McKeown, A, Rukazenkov, Y, Ohe, YVolume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy425
Date:
November, 2018
File:
PDF, 104 KB
english, 2018